On May 19, 2025, Fractyl Health, Inc. announced the submission of its first module for a Clinical Trial Application in Europe for RJVA-001, a gene therapy candidate from its Rejuva platform.
AI Assistant
FRACTYL HEALTH INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.